Publication
2016
Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Mathematical Models
|
Dynamic Transmission
|
Climate/Environment
|
Latin America & Caribbean
|
Health Systems
|
Cost-Effectiveness Analysis
|
Infectious Diseases
|
Child/Nutrition
|
Global Governance
|
Economics/Finance
|
Health/Medicine
|
Asia & Pacific